Physician profile
Peter P White
NPI 1407812969
$3,094.49
in general payments reported to CMS, 2019-2025
24 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $300 · 2021: $362 · 2022: $215 · 2023: $430 · 2024: $433 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $646.59 | 2019-2024 | Merlin@Home, Cardiomems |
| Janssen Pharmaceuticals, INC | $399.21 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $307.01 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $305.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.38 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $199.90 | 2019-2024 | Farxiga |
| Stryker Corporation | $173.75 | 2025 | Mako |
| Amgen INC. | $159.73 | 2019-2025 | Repatha |
| Novo Nordisk INC | $142.14 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $83.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $81.79 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $74.98 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $43.05 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $41.24 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.48 | 2019-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $31.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.94 | 2019 | |
| Merck Sharp & Dohme LLC | $22.75 | 2024 | Verquvo |
| Preventice Services, LLC | $20.14 | 2019 | |
| Lundbeck LLC | $19.73 | 2019 | |
| Bardy Diagnostics, INC. | $18.03 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2019 | |
| Medtronic, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.